TY - JOUR
T1 - Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2
T2 - SCORE 2 Report 15
AU - Etheridge, Tyler
AU - Blodi, Barbara
AU - Oden, Neal
AU - Van Veldhuisen, Paul
AU - Scott, Ingrid U.
AU - Ip, Michael S.
AU - Mititelu, Mihai
AU - Domalpally, Amitha
N1 - Funding Information:
Disclosure(s): All authors have completed and submitted the ICMJE disclosures form. I.U.S. serves as Principal Investigator and Chair of SCORE2, which is funded by the National Eye Institute, and has served as a consultant for Regeneron (Tarrytown, New Jersey) and on the Data and Safety Monitoring Committee of clinical trials sponsored by Novartis (Basel, Switzerland). M.S.I. is a consultant for Novartis, Genentech, Allergan, Regeneron, RegenexBio, Apellis, Aerie, Alimera, Amgen, Cell Lineage Therapeutics, Clearside, OCCURX. The remaining authors have no disclosures.
Funding Information:
Supported by the National Eye Institute ( National Institutes of Health , Department of Health and Human Services ) Grants U10EY023529 , U10EY023533 , and U10EY023521 . Support also provided in part by Regeneron , Inc., and Allergan , Inc., through donation of the investigational drug. Additional support provided in part by an unrestricted grant from Research to Prevent Blindness and a National Eye Institute Vision Research Core Grant ( P30 EY016665 ) to the University of Wisconsin School of Medicine and Public Health , Department of Ophthalmology and Visual Sciences, and to the Jules Stein Eye Institute and Doheny Eye Institute, Department of Ophthalmology at the University of California Los Angeles, California.
Funding Information:
Supported by the National Eye Institute (National Institutes of Health, Department of Health and Human Services) Grants U10EY023529, U10EY023533, and U10EY023521. Support also provided in part by Regeneron, Inc., and Allergan, Inc., through donation of the investigational drug. Additional support provided in part by an unrestricted grant from Research to Prevent Blindness and a National Eye Institute Vision Research Core Grant (P30 EY016665) to the University of Wisconsin School of Medicine and Public Health, Department of Ophthalmology and Visual Sciences, and to the Jules Stein Eye Institute and Doheny Eye Institute, Department of Ophthalmology at the University of California Los Angeles, California.
Publisher Copyright:
© 2020 American Academy of Ophthalmology
PY - 2021/10
Y1 - 2021/10
N2 - Purpose: To evaluate the association between baseline demographic and spectral domain OCT (SD-OCT) features with visual acuity (VA) in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) over 2 years. Design: Post hoc analysis of prospective clinical trial data. Participants: A total of 362 SCORE2 participants with macular edema secondary to central retinal (CRVO) or hemiretinal vein occlusion (HRVO). Methods: Spectral domain OCT volume scans were assessed at the SCORE2 reading center at baseline, month 01 (M01), month 06 (M06), month 12 (M12), and month 24 (M24) for central subfield thickness (CST), subretinal fluid, intraretinal fluid, vitreoretinal interface abnormalities, disorganization of retinal inner layers (DRIL), and ellipsoid zone (EZ) within the central subfield (CSF). Main Outcome Measures: Visual acuity at M06, M12, and M24. Results: Mean baseline age was 68.9 years. Mean VA at M01 was 63.2 letters, and CST was 299.7 μm. At M01, subretinal fluid was seen in 28.5% intraretinal fluid in 67.2%, DRIL was seen in 73.8%, mostly within the CSF, and the EZ was absent in 9.8 and patchy in 31.7%. In multivariate analysis including all M01 demographics and SD-OCT parameters and their association with VA at M06, M12, and M24, VA at M01 remained significant across all time points up to M24 (P < 0.001). Conclusions: In this 2-year follow-up of eyes that were treated with both per protocol and off protocol for RVO, VA at M01 was an important predictor of long-term vision and change in vision. Establishing predictors of visual recovery helps identify causes for poor responders to treatment in patients with RVO.
AB - Purpose: To evaluate the association between baseline demographic and spectral domain OCT (SD-OCT) features with visual acuity (VA) in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) over 2 years. Design: Post hoc analysis of prospective clinical trial data. Participants: A total of 362 SCORE2 participants with macular edema secondary to central retinal (CRVO) or hemiretinal vein occlusion (HRVO). Methods: Spectral domain OCT volume scans were assessed at the SCORE2 reading center at baseline, month 01 (M01), month 06 (M06), month 12 (M12), and month 24 (M24) for central subfield thickness (CST), subretinal fluid, intraretinal fluid, vitreoretinal interface abnormalities, disorganization of retinal inner layers (DRIL), and ellipsoid zone (EZ) within the central subfield (CSF). Main Outcome Measures: Visual acuity at M06, M12, and M24. Results: Mean baseline age was 68.9 years. Mean VA at M01 was 63.2 letters, and CST was 299.7 μm. At M01, subretinal fluid was seen in 28.5% intraretinal fluid in 67.2%, DRIL was seen in 73.8%, mostly within the CSF, and the EZ was absent in 9.8 and patchy in 31.7%. In multivariate analysis including all M01 demographics and SD-OCT parameters and their association with VA at M06, M12, and M24, VA at M01 remained significant across all time points up to M24 (P < 0.001). Conclusions: In this 2-year follow-up of eyes that were treated with both per protocol and off protocol for RVO, VA at M01 was an important predictor of long-term vision and change in vision. Establishing predictors of visual recovery helps identify causes for poor responders to treatment in patients with RVO.
UR - http://www.scopus.com/inward/record.url?scp=85102014212&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102014212&partnerID=8YFLogxK
U2 - 10.1016/j.oret.2020.12.016
DO - 10.1016/j.oret.2020.12.016
M3 - Article
C2 - 33373715
AN - SCOPUS:85102014212
SN - 2468-7219
VL - 5
SP - 991
EP - 998
JO - Ophthalmology Retina
JF - Ophthalmology Retina
IS - 10
ER -